Verdence Capital Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 4.3% in the 3rd quarter, ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Summary of Mount Sinai's New York BCI Symposium, by Synchron and Precision Neuroscience. Market Trends and forecast for brain ...

Deep Brain Stimulator MarketThe global deep brain stimulator market, valued at USD 1308.0 Million in 2024, is projected to grow steadily, reaching USD  2772.1 billion by 2034. With an anticipated CAGR ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

Inceptiv is a small device, implanted in the lower torso with leads to the spinal cord, that provides responsive counter-stimulation to relieve chronic pain. The device was approved by the FDA in ...

using spinal cord transcutaneous stimulation (scTS). This promising approach to enhance cardiovascular regulation addresses the challenges of unstable blood pressure and the accompanying ...

Spinal muscular atrophy (SMA) is a disorder affecting the motor neurons—nerve cells that control voluntary muscle movement. These cells are located in the spinal cord. Because the muscles cannot ...

Boston Scientific Corporation (NYSE:BSX) Q3 2024 Earnings Call Transcript October 23, 2024 Boston Scientific Corporation ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...